SCHEMBL1804264

SCHEMBL1804264

CN(CC(=O)O)c1ccc(P(=O)(O)O)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.42
CA4 P22748 1/20 0.42
CA5A P35218 1/20 0.42
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
GAA P10253 2/20 0.37
CA12 O43570 3/20 0.36
CA1 P00915 3/20 0.36
CA9 Q16790 3/20 0.36
KEAP1 Q14145 2/20 0.35
NFE2L2 Q16236 2/20 0.35
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NLRP3 Q96P20 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9512466 0.79 ENPP2 (0.42) CA2CA12CA1CA9
SCHEMBL797850 0.77 CA2 (0.43) CA2CA4CA5AGAACA12
SCHEMBL3348892 0.77 KEAP1 (0.54) CA2KMT2AGAACA12CA1
SCHEMBL196635 0.77 KMT2A (0.49) CA2MEN1KMT2ACYP2C19CA12
SCHEMBL5726224 0.76 TDP1 (0.46) CA2CYP1A2CYP2C19CA12CA1
SCHEMBL14364107 0.76 SLC6A9 (0.40) CA2CA12CA1CA9KEAP1
SCHEMBL8541381 0.76 ALDH1A1 (0.45) KEAP1NFE2L2TDP1ALDH1A1L3MBTL1
SCHEMBL9632043 0.76 TPMT (0.40) CA2MEN1KMT2AGAACA12
SCHEMBL3349309 0.76 MAPT (0.41) CA2CA12CA1CA9KEAP1
SCHEMBL10906215 0.76 ALDH1A1 (0.57) CA2MEN1KMT2ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011091033-A1 MODULATION OF NEUROGENESIS BY PPAR AGENTS BRAINCELLS, INC. (US) 2011-07-28 WO disclosed
WO-2011063115-A1 COMBINATION OF NOOTROPIC AGENT WITH ONE OR MORE NEUROGENIC OR NEUROGENIC SENSITIZING AGENTS FOR STIMULATING OR INCREASING NEUROGENESIS BRAINCELLS INC. (US) 2011-05-26 WO disclosed
EP-2125017-A2 MODULATION OF NEUROGENESIS WITH USE OF MODAFINIL Braincells, Inc. (US) 2009-12-02 EP disclosed
EP-2076288-A2 COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS Braincells, Inc. (US) 2009-07-08 EP disclosed
EP-2066355-A2 COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS Braincells, Inc. (US) 2009-06-10 EP disclosed
WO-2008097861-A2 MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS BRAINCELLS, INC. (US) 2008-08-14 WO disclosed
WO-2008086483-A2 MODULATION OF NEUROGENESIS WITH USE OF MODAFINIL BRAINCELLS, INC. (US) 2008-07-17 WO disclosed
WO-2008083204-A2 MODULATION OF NEUROGENESIS BY MELATONINERGIC LIGANDS BRAINCELLS, INC. (US) 2008-07-10 WO disclosed
WO-2008039863-A2 COMPOSITION COMPRISING A MELANOCORTIN RECEPTOR (MCR) MODULATING AGENT ALONE OR IN COMBINATION WITH A SECOND NEUROGENIC AGENT FOR TREATING NERVOUS SYSTEM DISORDERS BRAINCELLS, INC. (US) 2008-04-03 WO disclosed
WO-2008036678-A2 COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS BRAINCELLS, INC. (US) 2008-03-27 WO disclosed
WO-2008036846-A2 COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS BRAINCELLS, INC. (US) 2008-03-27 WO disclosed